Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab: A Randomized Controlled Trial
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 214
- 试验地点
- 1
- 主要终点
- The primary endpoint of the study is the endoscopic remission rate at week 16.
研究概览
简要总结
The goal of this clinical trial is to evaluate the efficacy and safety of dual-target therapy (Ustekinumab combined with Upadacitinib) versus intensified Ustekinumab monotherapy in patients with Crohn's disease who have an inadequate response to standard doses of Ustekinumab. The main questions it aims to answer are:
Is dual-target therapy more effective than intensified Ustekinumab monotherapy in achieving endoscopic remission in Crohn's disease patients?
Is dual-target therapy as safe as intensified Ustekinumab monotherapy in terms of adverse events?
Participants will:
Receive either dual-target therapy (Ustekinumab combined with Upadacitinib) or intensified Ustekinumab monotherapy.
Attend regular clinic visits for monitoring and assessments. Complete questionnaires about their symptoms and quality of life. Undergo routine blood tests and endoscopic evaluations to assess disease activity.
Researchers will compare the dual-target therapy group to the intensified Ustekinumab monotherapy group to see if dual-target therapy is more effective in achieving endoscopic remission and is as safe in terms of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants aged 18 to 70 years at baseline (week 0).
- •Active Crohn's Disease: Participants must have active Crohn's disease at baseline, defined as: CDAI > 150 and Endoscopic activity with SES-CD > 6, or SES-CD > 4 (for isolated ileal disease), excluding the contribution of the stricture component (Excluding the stricture component ensures recruitment of patients with a better chance of improvement, given the primary endpoint is endoscopic remission), and at least one of the following: CRP > 10 mg/L (upper limit of normal on local assay), Fecal calprotectin (FC) > 250 μg/g, active disease confirmed by imaging.
- •Prior Ustekinumab Treatment: Participants must have had primary non-response or secondary loss of response to TNFi, and have undergone at least 16-24 weeks of standard-dose ustekinumab treatment, but still have active CD.
- •Consent and Compliance: Participants must be capable and willing to provide written informed consent and comply with the requirements of the study protocol.
- •General Health: The principal investigator (or designee) must determine that the participant is in good general health based on medical history, laboratory test results, physical examination, chest X-ray (CXR), and 12-lead electrocardiogram (ECG) obtained during the screening period.
排除标准
- •Allergies: Participants with known allergies to UPA or UST excipients or components.
- •Colonic Neoplasia: Participants with untreated or unresolved high-grade dysplasia or colon cancer.
- •Active Infections: Participants with active infections at screening or baseline, including but not limited to pneumonia, pyelonephritis, or herpes zoster, or those with evidence of chronic infections that make them unsuitable for the study as per the investigator's assessment.
- •Surgical Intervention: Participants who currently require or are expected to require surgical intervention for CD during the study period.
- •Thrombosis: Participants with thrombosis identified through limb venous Doppler ultrasound or D-dimer screening.
- •Lymphoproliferative Disorders: Participants with a history of lymphoproliferative disorders, including lymphoma, or those with signs and symptoms indicative of possible lymphoproliferative disease such as lymphadenopathy and/or splenomegaly.
- •Immunodeficiency: Participants with any known congenital or acquired immunodeficiency, including common variable immunodeficiency, HIV infection, or organ transplantation.
- •Pregnancy: Female participants with a positive pregnancy test at screening or baseline (week 0).
- •Lactation or Pregnancy Plans: Female participants who are breastfeeding or planning to become pregnant during the study.
- •Substance Abuse: Participants with a history of drug abuse (defined as the use of any illicit drug) or alcohol abuse within 1 year prior to screening.
- •Investigator's Discretion: Participants deemed unsuitable for the study by the investigator for any reason.
研究组 & 干预措施
Dual-target Therapy Group
Participants in this group will receive the standard maintenance dosage of Ustekinumab administered subcutaneously, combined with the addition of Upadacitinib administered orally.
干预措施: Ustekinumab and Upadacitinib (Drug)
Intensified Ustekinumab Monotherapy Group
Participants in this group will receive an additional induction dose of Ustekinumab administered intravenously, followed by maintenance therapy with Ustekinumab.
干预措施: Ustekinumab (Drug)
结局指标
主要结局
The primary endpoint of the study is the endoscopic remission rate at week 16.
时间窗: Week 16
Endoscopic remission is defined as an SES-CD score of less than 3, with no individual variable subscore exceeding 1.
次要结局
- Biochemical remission rate at week 16(Week 16)
- Normalization rate of intestinal wall thickness on ultrasound at week 16(Week 16)
- Health-related quality of life assessment using the Inflammatory Bowel Disease Questionnaire (IBDQ)(Week 16 and around Week 52)
- Clinical response rate at week 16(Week 16.)
- Normalization rate of fecal calprotectin levels at week 16(Week 16)
- Endoscopic response rate at week 16(Week 16)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at week 16.(Week 16)
- Deep remission rate at week 16(Week 16)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at week 52(Around Week 52)
研究者
Wei Wang
Principal Investigator
Sixth Affiliated Hospital, Sun Yat-sen University